Zacks Investment Research
04 Aug 2026, 13:51 UTC · 4h ago
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
04 Aug 2026, 13:51 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Harmony Biosciences reported quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $0.97. — A significant earnings beat (31.96%) generally triggers positive short-term price action for the specific ticker.
+0.40Harmony Biosciences posted quarterly revenues of $261.28 million, exceeding the consensus estimate by 3.46%. — Revenue growth and a beat indicate improving top-line health, supporting the earnings surprise.
+0.20Harmony Biosciences shares have declined approximately 4.9% year-to-date, underperforming the S&P 500's 11% gain. — Establishes a bearish trend and relative weakness for the stock despite the current quarterly beat.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company beat both earnings and revenue estimates for the quarter with a significant positive earnings surprise.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
3h ago
